Brind.

Ollin Biosciences is developing compounds (OLN102, OLN324) that target and challenge the market share of Amgen's Tepezza and Vabysmo.

1 report, 1 independent Updated Jun 24

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Amgen Innovent Biologics Hoffmann-La Roche

Keep exploring

The entities involved

Amgen
American multinational biopharmaceutical company
- Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
- Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05
Innovent Biologics
Chinese Biopharmaceutical Company

Nothing else this week.
Hoffmann-La Roche
Swiss healthcare company
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
- Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08

Coverage

Newest first; wire copies grouped

Jun 24biopharmadive.com